Phase III trial of orally administered ibandronic acid, compared with intravenously administered ibandronic acid (Bonviva IV Injection), in patients with osteoporosis in Japan.
Phase of Trial: Phase III
Latest Information Update: 01 May 2018
At a glance
- Drugs Ibandronic acid (Primary) ; Ibandronic acid
- Indications Osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms MOVEST
- Sponsors Chugai Pharmaceutical; Taisho Pharmaceutical
- 17 Apr 2016 Results of sub-group analysis (n=422) presented at the 2016 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
- 22 Jan 2016 According to Chugai Pharmaceuticals media release, company has filed a new drug application to the MHLW.
- 22 Jan 2016 Results published in Chugai Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History